Evolus, Inc. (EOLS) Stock Score, Valuation & Financial Research
Evolus, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for EOLS
Evolus, Inc. currently has a Wall Street Score of 24/100. The stored market price is $7.84. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Evolus, Inc. does
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $7.84
- Market capitalization:
- $516.3M
- Revenue:
- $316.5M
- Net income:
- $-34.3M
- Free cash flow:
- $-50.7M
- Cash:
- $45.2M
- Total debt:
- $164.8M
- EPS:
- -0.52
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-50.7M, showing cash burn in the current stored period.
- The balance sheet shows $45.2M of cash versus $164.8M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EOLS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.